Home โบ Lymphoma
Lymphoma clinical trials recruiting in the U.S.
142 studies for Lymphoma are recruiting participants at sites across the United States.
Lymphoma is a cancer affecting the immune system. Hodgkins Lymphoma and Non Hodgkins Lymphoma are types of lymphoma. Learn about symptoms and treatments.
Cities with the most studies
- Houston, TX34 studies
- Boston, MA33 studies
- New York City, NY33 studies
- Washington, DC23 studies
- Baldwin Park, CA21 studies
- Chicago, IL20 studies
- Durham, NC17 studies
- St. Louis, MO15 studies
- Philadelphia, PA15 studies
- Cleveland, OH14 studies
- Edison, NJ12 studies
- Atlanta, GA12 studies
- Seattle, WA12 studies
- Salt Lake City, UT11 studies
- Rochester, MN11 studies
- Nashville, TN11 studies
- Columbus, OH11 studies
- Miami, FL11 studies
- Los Angeles, CA10 studies
- Pittsburgh, PA10 studies
- Dallas, TX10 studies
- Queens, NY10 studies
- Mountain View, CA9 studies
- Denver, CO9 studies
- Greenburgh, NY9 studies
- Portland, OR9 studies
- Milwaukee, WI9 studies
- Aurora, CO8 studies
- Birmingham, AL8 studies
- Staten Island, NY8 studies
- East Norwalk, CT8 studies
- Cincinnati, OH8 studies
- San Antonio, TX7 studies
- Tampa, FL7 studies
- New Haven, CT7 studies
- New Rochelle, NY7 studies
- Omaha, NE7 studies
- Phoenix, AZ7 studies
- Kansas City, MO6 studies
- Baltimore, MD6 studies
By state
- Alabama9 studies
- Arizona11 studies
- Arkansas3 studies
- California40 studies
- Colorado16 studies
- Connecticut7 studies
- District of Columbia7 studies
- Florida25 studies
- Georgia16 studies
- Illinois23 studies
- Indiana6 studies
- Iowa6 studies
- Kansas7 studies
- Kentucky5 studies
- Maryland21 studies
- Massachusetts33 studies
- Michigan12 studies
- Minnesota14 studies
- Missouri17 studies
- Nebraska7 studies
- New Jersey18 studies
- New York42 studies
- North Carolina22 studies
- Ohio29 studies
- Oklahoma4 studies
- Oregon9 studies
- Pennsylvania24 studies
- South Carolina4 studies
- Tennessee15 studies
- Texas45 studies
- Utah14 studies
- Virginia10 studies
- Washington12 studies
- Wisconsin12 studies
Recently updated studies
CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
RecruitingPhase 1
Ages 12 to 75 ยท All sexes ยท Updated Oct 2, 2026 ยท NCT02917083Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
RecruitingPhase 2
Ages 12 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT03258567Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RecruitingObservational study
Ages 3 and older ยท All sexes ยท Updated Oct 2, 2026 ยท NCT01441089Rutgers University Study of the Genetics of Blood Cancers
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 110 ยท All sexes ยท Updated Oct 1, 2026 ยท NCT07714044T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RecruitingPhase 1/2
Ages 18 and older ยท All sexes ยท Updated Oct 1, 2026 ยท NCT06343311Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 ยท All sexes ยท Updated Oct 1, 2026 ยท NCT06131801CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
RecruitingPhase 1/2
Ages 3 to 39 ยท All sexes ยท Updated Sep 30, 2026 ยท NCT05442515A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 30, 2026 ยท NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 30, 2026 ยท NCT07015242A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
RecruitingPhase 2
1 Month โ 17 Years ยท All sexes ยท Updated Sep 30, 2026 ยท NCT04570423Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 29, 2026 ยท NCT07583810Specimen Collections From Participants With HIV Infection, KSHV Infection, Viral-Related Pre-malignant Lesions and Cancer
RecruitingObservational study
Ages 18 to 120 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT00006518A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
Recruiting
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07013435Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
Recruiting
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT07014293Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 28, 2026 ยท NCT03418038Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT00923507Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
RecruitingPhase 1/2
Ages 18 to 120 ยท All sexes ยท Updated Sep 28, 2026 ยท NCT03223610A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
RecruitingPhase 1/2
Up to age 25 ยท All sexes ยท Updated Sep 25, 2026 ยท NCT04094610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
RecruitingPhase 1
24 Months โ 18 Years ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06441331Epco, Zanu, Ritux for R/R FL or MZL
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 25, 2026 ยท NCT06563596Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT06398457Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
RecruitingPhase 2
Ages 18 and older ยท All sexes ยท Updated Sep 24, 2026 ยท NCT02974647CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
RecruitingPhase 2
Ages 18 to 99 ยท All sexes ยท Updated Sep 24, 2026 ยท NCT04083495Precise Oncology Interventions in Nutrition and Training (OnPoint)
RecruitingHealthy volunteers welcome
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT06534918Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
RecruitingPhase 1
Ages 18 and older ยท All sexes ยท Updated Sep 23, 2026 ยท NCT04301076From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.